BridgeBio Oncology Therapeutics Inc.
Support and Resistance Levels
Past performance
News About BBOT
All events for BBOT
All deals for BBOT
Financial Ratios
Financial Statements
BBOT vs Sector & Peers
About BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer. Website bbotx.com
Headquarters South San Francisco, CA, US